Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Copper gluconate/disulfiram - Cantex Pharmaceuticals

Drug Profile

Copper gluconate/disulfiram - Cantex Pharmaceuticals

Alternative Names: CX 02; Dicopp; Disulfiram/copper gluconate - Cantex Pharmaceuticals; DSF-Cu

Latest Information Update: 24 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cantex Pharmaceuticals
  • Class Antineoplastics; Heavy metals; Small molecules
  • Mechanism of Action Aldehyde dehydrogenase inhibitors; Cell death stimulants; Proteasome inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Pancreatic cancer; Prostate cancer
  • Phase I Multiple myeloma; Myelodysplastic syndromes
  • No development reported Brain metastases; Triple negative breast cancer

Most Recent Events

  • 06 Feb 2022 Cantex Pharmaceuticals terminates phase I trial in Multiple myeloma (Second-line therapy or greater) in USA (unspecified route) (NCT04521335)
  • 01 Oct 2021 Phase-I clinical trials in Myelodysplastic syndromes in USA (PO) (Cantex Pharmaceuticals, September 2021)
  • 20 Sep 2021 Cantex Pharmaceuticals has patent protection for copper gluconate/disulfiram (Cantex Pharmaceuticals pipeline, September 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top